#NEWS: Bayer has initiated a Phase III trial for a new targeted therapy in HER2-mutant non-small cell lung cancer (#NSCLC). Read more here: http://spr.ly/6048mwBpr #HealthForAll #HungerForNone #TeamBayer #Oncologyinspired
Great news for patients and the whole industry. Wishing success and positive outcomes!
With emphasis on improving survival rates, Bayer's proactive approach embodies the evolution of cancer therapy towards more tailored and effective strategies, responding to the urgent need for breakthrough solutions in a field that has seen stagnation in specialized treatments.
Wonderful news, bringing forward innovation!
Great news for patients.
Wishing success!
Magnífico
Thats great news!
Member of the Executive Committee of Bayer AG`s Pharmaceuticals Division and Head, Global Product Strategy and Commercialization
2moThis is an important milestone for an underserved patient population. Impacting people as young as 30, HER2-mutant NSCLC is a devastating disease, with poor prognosis. Novel therapies are urgently needed, and I’m proud to see #TeamBayer advance our mission through the power of precision medicine